Hans-Peter Gerber Biography and Net Worth

Hans-Peter Gerber, Ph.D., has served as Chief Scientific Officer of Sutro since September 2023, bringing more than three decades experience in advancing transformative biologics in oncology, with deep expertise in antibody-drug conjugates (ADCs), redirected T-cell engagers, and cell-based immunotherapies.

Prior to Sutro, Hans-Peter co-founded Codeable Therapeutics in 2022 to advance next-generation ADCs engineered to elicit immunogenic cell death and deepen antitumor immune responses. He also served as Chief Scientific Officer and SVP at 3T Biosciences, where he completed an oversubscribed Series A while serving as interim Chief Executive Officer. Previously, Hans-Peter built the R&D organization at Maverick Therapeutics, leading to its acquisition by Takeda in 2021, and served as an independent director at NBE Therapeutics, acquired by Boehringer Ingelheim in 2021.

Earlier in his career, he held scientific leadership roles at Genentech, Seattle Genetics, and Pfizer, overseeing multiple oncology programs from discovery through IND submission. His work contributed to more than 10 IND filings, including seven ADCs, and to three BLAs, including Avastin®, Mylotarg®, and Besponsa®.

An internationally recognized leader in oncology R&D, Hans-Peter has authored over 100 peer-reviewed publications, holds over 100 patents, and has contributed to the development of six of the 15 FDA-approved ADCs. He also serves as Chairman of the Board at T-CURX in Germany and as a board member at Athebio in Switzerland. Hans-Peter received his M.S. in Biochemistry and Ph.D. in Molecular Biology from the University of Zurich, Switzerland.

What is Hans-Peter Gerber's net worth?

The estimated net worth of Hans-Peter Gerber is at least $246.74 thousand as of October 15th, 2025. Dr. Gerber owns 7,183 shares of Sutro Biopharma stock worth more than $246,736 as of April 22nd. This net worth evaluation does not reflect any other investments that Dr. Gerber may own. Learn More about Hans-Peter Gerber's net worth.

How do I contact Hans-Peter Gerber?

The corporate mailing address for Dr. Gerber and other Sutro Biopharma executives is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. Sutro Biopharma can also be reached via phone at (650) 392-8412 and via email at [email protected]. Learn More on Hans-Peter Gerber's contact information.

Has Hans-Peter Gerber been buying or selling shares of Sutro Biopharma?

Hans-Peter Gerber has not been actively trading shares of Sutro Biopharma during the past quarter. Most recently, on Wednesday, October 15th, Hans-Peter Gerber bought 1,700 shares of Sutro Biopharma stock. The stock was acquired at an average cost of $8.00 per share, with a total value of $13,600.00. Following the completion of the transaction, the insider now directly owns 7,183 shares of the company's stock, valued at $57,464. Learn More on Hans-Peter Gerber's trading history.

Who are Sutro Biopharma's active insiders?

Sutro Biopharma's insider roster includes Gregory Chow (Chief Financial Officer), Hans-Peter Gerber (Chief Scientific Officer), Connie Matsui (Director), David Pauling (Insider), and Nicki Vasquez (Insider). Learn More on Sutro Biopharma's active insiders.

Are insiders buying or selling shares of Sutro Biopharma?

During the last year, Sutro Biopharma insiders bought shares 5 times. They purchased a total of 11,175 shares worth more than $89,597.50. The most recent insider tranaction occured on October, 15th when insider Hans-Peter Gerber bought 1,700 shares worth more than $13,600.00. Insiders at Sutro Biopharma own 5.9% of the company. Learn More about insider trades at Sutro Biopharma.

Information on this page was last updated on 10/15/2025.